Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-05
2011-07-05
Kishore, Gollamudi (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S617000
Reexamination Certificate
active
07973034
ABSTRACT:
This disclosure relates to amides, aryl sulphonamides, aryl ureas, and α,β-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.
REFERENCES:
patent: 4046918 (1977-09-01), Cebrian
patent: 5726314 (1998-03-01), Powers et al.
patent: 6407117 (2002-06-01), Bouscarel et al.
patent: 6565842 (2003-05-01), Sojomihardjo et al.
patent: 6800483 (2004-10-01), Danks et al.
patent: 7018631 (2006-03-01), Danks et al.
patent: 7419987 (2008-09-01), Hofgen et al.
patent: WO 99/42593 (1999-08-01), None
patent: WO-99/55663 (1999-11-01), None
Berndt et al. (Journal of the American Chemical Society (1977), 99(25), 8332-4).
Wadkins et al. Journal med. chem. 2005, 48, 2906-2915.
Slatter et al. “Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.” Drug Metabolism and Disposition. 1997. vol. 25, No. 10. pp. 1157-1164.
Atsumi et al. “The production of reactive oxygen species by irradiated camphorquinone-related photosensitizers and their effect on cytotoxicity.” Archives of Oral Biology. 2001. vol. 46. pp. 391-401.
Wadkins et al. “Identification and Characterization of Novel Benzil (Diphenylethane-1,2-dione) Analogues as Inhibitors of Mammalian Carboxylesterases.” Journal of Medicinal Chemistry. 2005. vol. 48, No. 8. pp. 2906-2915.
Joseph Kraut, “Serine Proteases: Structure and Mechanism of Catalysis”, Ann. Rev. Biochem. vol. 46, pp. 331-358, 1977.
E.R. Soares, “Identification of a New Allele ofEs-lSegregating in an Inbred Strain of Mice”, Biochemical Genetics, vol. 17, Nos. 7/8, pp. 577-583, 1979.
Akihiko Tanizawa, et al. “Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials”, Journal of the National Cancer Institute, vol. 86, No. 11, pp. 836-841, 1994.
Michael C. Bemdt, et al., “Inhibition of Chicken Liver Carboxylesterase by Activated Carbonyls and Carbonyl Hydrates”, Biochimica et Biophysica Acta, 1298, pp. 159-166, 1996.
Christopher L. Morton, et al., “Comparison ofEscherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 Cells for Recombinant Gene Expression—Application to a Rabbit Liver carboxylesterase”, Molecular Biotechnology, vol. 16, pp. 193-202, 2000.
Gialih Lin, et al.; “Quantitative Structure-Activity Relationships for the Pre-Steady-State Inhibition of Cholesterol Esterase by 4-Nitrophenyl-N-substituted Carbamates”, Bioorganic & Medicinal Chemistry, vol. 8, pp. 2601-2607, 2000.
Ruchi Khanna, et al., “Proficient Metabolism of Irinotecan by a Human Intestinal Carboxylesterase”, Cancer Research, vol. 60, pp. 4725-4728, 2000.
Randy M. Wadkins, et al. Structural Constraints Affect the Metabolism of 7-Ethyl-10-[4-(1-peperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by Carboxylesterases, Molecular Pharmacology, vol. 60, No. 2, pp. 355-362, 2001.
Monika Wierdl, et al. “Sensitization of Human Tumor Cells to CPT-11 via Adenoviral-Mediated Delivery of a Rabbit Liver Carboxylesterase”, Cancer Research, vol. 61, pp. 5078-5082, Jul. 1, 2001.
P. Bar-On, et al., “Kinetic and Structural Studies on the Interaction of Cholinesterases with the Anti-Alzheimer Drug Rivastigmine”, Biochemistry, vol. 41, pp. 3555-3564, 2002.
Kyoung Jin P. Yoon, et al. Synthesis and Evaluation of Esters and Carbamates to Identify Critical Functional Groups for Esterase-specific Metabolism, Bioorganic & Medicinal Chemistry, vol. 11, pp. 3237-3244, 2003. (Available online Jun. 11, 2003).
Randy M. Wadkins, et al. “Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity”, Molecular Pharmacology, vol. 56, pp. 1336-1342, 2004.
Berndt et al., 1977, “Ethyl Phenylglyoxylate, a Simultaneous Inhibitor and Substrate of Chicken Liver Carboxylesterase (EC 3.1.1.1). Enzyme-Catalyzed Fragmentation of (E)-Benzil Monoxime O-2,4-Dinitrophenyl Ether”,J. American Chem. Soc., 99:8334-5.
Beroza Paul P.
Damoradan Komath V.
Hyatt Janice Louise
Morton Christopher Lee
Potter Philip Michael
Fish & Richardson P.C.
Kishore Gollamudi
Maewall Snigdha
St. Jude Children's Research Hospital
LandOfFree
Amide, aryl sulfonamide, aryl urea, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide, aryl sulfonamide, aryl urea, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide, aryl sulfonamide, aryl urea, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674311